GRAY Graybug Vision Inc.

Biotech Analyst Ratings

Latest News

1. 10 May 2022 Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments

   BALTIMORE, May 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported financial results for the quarter ended March 31, 2022.
   

   Recent Corporate Developments

   • Committed to advancing GB-102 into additional wet-AMD clinical trial — enhanced formulation of GB-102, designed to reduce or eliminate microparticle dispersion, has been developed for an additional Phase 2 trial to further evaluate safety, efficacy and durability demonstrated in the ALTISSIMO trial.
   • Expanded pipeline with novel gene therapy to address rare vision-threatening …

   View Full Article
2. 27 April 2022 Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

   BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary open-angle glaucoma (POAG) at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held at the Colorado Convention Center in Denver from May 1-4, 2022.
   

   Information is listed below and available on the ARVO website.

   In Vitro and In Vivo Characterizations of GB-401, a Sustained-Release Intravitreal Implant Containing a Beta-Adrenergic Antagonist Prodrug for POAG
   Presenter: Yun Yu, PhD, Associate Director R&D…

   View Full Article
3. 18 April 2022 Graybug to Present at the 2022 ASCRS Annual Meeting

   BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, to be held in Washington, D.C. from April 22-26, 2022.

   Information is listed below and available on the ASCRS program planner.

   Intrastromal delivery of AAV-IDUA for MPS1-associated corneal clouding
   Presenter: Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision
   Session: GS-3 ASCRS Innovators General Session Date and Time: Monday April 25, 2022; 10 AM - 12 PM ET
   Location: Walter E. Washington…

   View Full Article
4. 13 April 2022 Graybug Vision Appoints Dirk Sauer to Board of Directors

   BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced the appointment of Dirk Sauer, PhD, to the Graybug Board of Directors, effective April 13, 2022. Dr. Sauer will serve as a member of the Nomination and Corporate Governance Committee of the Board. He will also chair the Science and Innovation Committee, the purpose of which is to advise the Board on the company's research and development as well as clinical manufacturing and control strategies.
   

   Dr. Sauer succeeds Gerald Cagle, PhD, who is retiring from the Graybug Board after eight years of service. Dr. Cagle will continue…

   View Full Article
5. 30 March 2022 Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023

   • Phase 2 trial with optimized formulation in wet AMD expected to start in fourth quarter of 2022
   • Phase 1 trial in glaucoma expected to commence in first quarter of 2023
   • Acquired corneal gene therapy program; Phase 1/2a data expected in fourth quarter of 2023
   • New programs for Retinitis Pigmentosa and Geographic Atrophy
   • Current cash expected to fund planned operations into fourth quarter of 2023
   • Graybug to host virtual Investor R&D Day today, March 30, 2022, beginning at 11 a.m. ET

   BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (NASDAQ:GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a strategic update on its pipeline programs…

   View Full Article